Navigation Links
Alchemia Reports Preliminary Positive Efficacy Data From HyCAMP,Phase II Trial

ure studies with the FDA. We are hopeful that these results will enable us to move forward to a pivotal phase III study earlier than originally anticipated."

These results are important not only for the development and approval path for HyCAMP(TM) itself but they provide validation of the technology platform. The HyACT(TM) platform is an extremely flexible formulation technology as it can be used with virtually any intravenously administered anti-cancer treatment. We have successfully completed Phase I clinical studies on HyACT(TM) formulations of two other chemotherapy drugs, doxorubicin and 5- flurouracil. Encouraging preclinical data has also been obtained on a number of other cytotoxics. More recently, we have demonstrated in preclinical studies that HyACT(TM) can also be used to significantly enhance the efficacy of newer targeted antibody therapies such as Avastin(TM) and Erbitux(TM) In the case of generic drugs or drugs close to patent expiry, the HyACT(TM) formulation may provide a means for companies to differentiate their products from other competitors in the market place, and thereby build product value.

HyCAMP(TM) and the proprietary formulation technology, HyACT(TM), were obtained following the successful acquisition of Melbourne based oncology company Meditech Research Limited in 2006. "The Phase II clinical results provide proof of concept for the HyACT(TM) platform. We expect this technology to build substantial value for shareholders, not only with HyCAMP(TM), but with other oncology drugs as well" Dr Ramsdale said.

Before HyCAMP(TM) can be marketed in the US, the drug needs to successfully complete a Phase III study, and receive marketing approval from the US FDA.

Alchemia wishes to acknowledge the commitment and thank the patients who volunteered to participate in this trial, and to acknowledge and thank the investigators, study research personnel and nursing staff at the 10 clinical sites across Australia who looked a
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
2. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
3. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
4. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
5. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
9. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
10. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
11. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
Post Your Comments:
(Date:8/19/2014)... , Aug. 19, 2014 Research and ... Products - Global Strategic Business Report" report to their ... for Anti-Adhesion Products in US$ Thousands by the following three ... Procedures. The report provides separate comprehensive analytics for ... , Europe , Asia-Pacific ...
(Date:8/18/2014)... and HERZLIYA-PITUACH, Israel , Aug. ... OMX First North Premier, Stockholm : "IMNP"), ... that its application to list its common stock on the ... Market, a unit of the NASDAQ OMX Group. IMMUNE,s common ... Market at the opening of trading on August 21, 2014 ...
(Date:8/18/2014)... 2014 Reportlinker.com announces that a new market ... Russia Sinuscopes Market Outlook to 2020 ... Market Outlook to 2020 Summary ... 2020", provides key market data on the Russia Sinuscopes ... dollars, volume (in units) and average prices (in US ...
Breaking Medicine Technology:Global Anti-Adhesion Products - Strategic Business Report 2014 2Immune Pharmaceuticals Announces Approval for Listing on the NASDAQ Capital Market 2Immune Pharmaceuticals Announces Approval for Listing on the NASDAQ Capital Market 3Immune Pharmaceuticals Announces Approval for Listing on the NASDAQ Capital Market 4Russia Sinuscopes Market Outlook to 2020 2Russia Sinuscopes Market Outlook to 2020 3Russia Sinuscopes Market Outlook to 2020 4
... , SCOTTSDALE, Ariz. , Jan. 22 Matrixx Initiatives, ... financial results for the fiscal 2010 third quarter, ended December 31, ... January 25, 2010 . An earnings conference call will be held the ... AM ET . , To access the teleconference, please call (888) 452-4006 ...
... ... Called Ampyra, to Improve Walking for People With All Types of ... The U.S. Food and Drug Administration has approved the ... Therapeutics) for its ability to improve walking speed in people with ...
Cached Medicine Technology:Matrixx Initiatives, Inc. Sets Time for Discussion of Third Quarter Fiscal 2010 Financial Results 2Ampyra is First Symptom Management Drug Developed Specifically to Treat MS, the First Oral MS Therapy Approved for MS, and the First New FDA Approved Therapy to Come Through the MS Pipeline Since 2004 2Ampyra is First Symptom Management Drug Developed Specifically to Treat MS, the First Oral MS Therapy Approved for MS, and the First New FDA Approved Therapy to Come Through the MS Pipeline Since 2004 3Ampyra is First Symptom Management Drug Developed Specifically to Treat MS, the First Oral MS Therapy Approved for MS, and the First New FDA Approved Therapy to Come Through the MS Pipeline Since 2004 4Ampyra is First Symptom Management Drug Developed Specifically to Treat MS, the First Oral MS Therapy Approved for MS, and the First New FDA Approved Therapy to Come Through the MS Pipeline Since 2004 5Ampyra is First Symptom Management Drug Developed Specifically to Treat MS, the First Oral MS Therapy Approved for MS, and the First New FDA Approved Therapy to Come Through the MS Pipeline Since 2004 6
(Date:8/19/2014)... editorial published in this week,s JAMA highlights ... tools when considering how to treat patients. Written by ... Center and chair of pediatrics at Boston University School ... JAMA , the editorial examines results of a study ... an example of how doctors can often over-emphasize certain ...
(Date:8/19/2014)... Kars4Kids , a national nonprofit organization ... partnership with New York State Senator Gustavo Rivera to ... The giveaway will take place in conjunction with Rivera’s ... August 22. , “With a mission focused on ... children for school with the necessary supplies is imperative,” ...
(Date:8/19/2014)... August 19, 2014 “ Inbox Blueprint ... course designed to provide users with the tools necessary ... marketing techniques and strategies. The course which was ... of excitement throughout the internet marketing world. The commotion ... HonestyFirstReviews.com's Tiffany Hendricks prompting an updated review of the ...
(Date:8/19/2014)... (HealthDay News) -- Lupus and other rheumatic diseases ... seizures, which can delay a correct diagnosis for ... rheumatic diseases can also cause these types of ... Center in Maywood, Ill. Rheumatic disorders include ... soft tissues, such as lupus, systemic vasculitis and ...
(Date:8/19/2014)... 2014 In honor of National Dog Day on ... old furry friend by offering tips on caring for aging dogs. ... more. Because of this, dog owners need to realize the dog’s ... age, their needs change. They will not want to spend as ... used to. Because of this, pet owners should consider altering the ...
Breaking Medicine News(10 mins):Health News:Review of clinical treatment of bronchiolitis in infants reveals over-reliance on one test 2Health News:Backpack Giveaway Kars4Kids Partners with New York State Senator Gustavo Rivera to Prepare Bronx Students for New School Year 2Health News:Anik Singal’s “Inbox Blueprint” Review Released By HonestyFirstReviews.com 2Health News:Certain Symptoms Can Delay Lupus Diagnosis, Researchers Report 2Health News:The Puppy Store Helps Pet Owners Care for Aging Dogs 2
... April 17 Even though suicide outranks homicide as ... death certificates thwart healthcare policymakers who want to create ... a WVU study shows."The Institute of Medicine ... have been diagnosed with a mental disorder, but death ...
... slumber , , FRIDAY, April 17 (HealthDay News) -- Over-the-counter ... with autism, a small U.S. study shows. , The ... with autism spectrum disorder, fragile X syndrome (FXS), or ... or a placebo for two weeks. After they completed ...
... partner and accomplished medical malpractice litigator Gary S. Genovese ... most recently of Martin, Lister, Alvarez & Genovese PLC ... and has had his cases featured in USA Today, ... He is well known for litigating cases throughout the ...
... where people are watching their spending, prescription discount card ... pricesWARRENSVILLE HEIGHTS, Ohio, April 17 The ... help provide its residents with some relief from the ... making free prescription drug discount cards available to city ...
... Recent economic events have led people to re-examine ... Many are feeling that it is time to get ... they are deciding to start their families now, instead ... is reflected in a growing number of couples who ...
... new German technology to process the conversion of medical records from ... ... April 17, 2009 -- Penny Imaging Exchange, Inc. (PIE) has acquired ... to digital form - the DRS Digitizer . With the ...
Cached Medicine News:Health News:Team Uncovers Discrepancy in Death Certificates Listing Suicide 2Health News:Melatonin May Ease Sleep Problems in Autistic Children 2Health News:Veteran Medical Malpractice Litigator Gary S. Genovese Re-Joins Conrad & Scherer LLP 2Health News:City of Warrensville Heights Residents Have Access to Easy-to-Use Prescription Drug Discount Card Launched Today 2Health News:Family Cocooning in the Face of Recession Leads to Expanded Business for Bay Area Fertility Doctor - Dr. Danielle Lane 2Health News:Penny Imaging Exchange, Inc. Acquires New Technology to Capture Medical Records from Microfiche 2Health News:Penny Imaging Exchange, Inc. Acquires New Technology to Capture Medical Records from Microfiche 3
... doubled Nd:YAG laser is mounted on Haag ... selected between 0.2 and 2.0 mJ. The ... and 700 microns. Knobs for laser energy ... on the laser head. The laser system ...
... Tango ophthalmic laser system provides two lasers ... and a photodisruptor for posterior capsulotomy and ... Nd:YAG producing pulsed 532 nm light. The ... nm. The appropriate laser can be easily ...
... Glaucoma Laser System features a patented technique ... glaucoma. It selectively targets pigmented cells and ... Selecta II is equipped with a Q-switch ... light, which induces the same cell replacement ...
Thin and smooth jaws, designed to enter trough 3 mm incision, cross action....
Medicine Products: